How NexLife and Ro Body compare on price, medication type, clinical oversight, and pharmacy transparency — with the trade-offs and who each may suit.
| NexLife | Ro Body | |
|---|---|---|
| From / month | $186/mo* | $349+/mo |
| Pricing model | Flat, dose-independent | Varies — see provider |
| Medication type | Compounded tirzepatide | Brand (Zepbound/Mounjaro) |
| FDA status | Not FDA-approved (compounded) | FDA-approved |
| Clinical oversight | MD/DO-supervised | MD-led |
| Pharmacy / fulfillment | 503A & 503B (six disclosed) | Manufacturer / retail pharmacy |
| What's included | Meds, visits, labs, coaching | Brand medication, provider visits, insurance prior-auth assistance |
| Insurance | Cash-pay (HSA/FSA) | Insurance prior-auth support |
Pricing verified as of July 2026 — confirm current figures with each provider. Compounded medications are not FDA-approved.
NexLife uses MD/DO-supervised care with included lab review and titration support. Ro Body operates a md-led model (brand (zepbound/mounjaro)). Eligibility and any prescription are determined by a licensed clinician in both cases, and outcomes are not guaranteed.
NexLife discloses six partner pharmacies across the 503A and 503B pathways and offers certificates of analysis on request. Ro Body fulfillment: Manufacturer / retail pharmacy. Compounded products from either pathway are not FDA-approved — see 503A vs 503B.
NexLife may suit you if you want predictable flat pricing that doesn't rise with dose, MD/DO oversight, disclosed pharmacies, and bundled labs/coaching — and you're comfortable with compounded medication (not FDA-approved) paid cash-pay.
Ro Body may suit you if you want an FDA-approved brand-name product and/or insurance pathways, and are comfortable with a higher or coverage-dependent cost.
As of July 2026, NexLife starts at $186/month flat. Ro Body is listed from $349+/mo. Compare total annual cost including visits and labs, not just the headline price. Compounded tirzepatide is not FDA-approved. See NexLife pricing
NexLife is flat-rate compounded tirzepatide with MD/DO oversight and disclosed 503A/503B pharmacies; Ro Body is brand (zepbound/mounjaro) with a md-led model. Choose based on whether you want compounded vs brand, flat vs variable pricing, and your insurance situation.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.